Please assess the completion status of the following clinical trial:

Trial Title: Single-arm Study of Symplicity™ Renal Denervation System in Patients With Uncontrolled HyperTensioN in India

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Individual is 18 and 80 years old at time of treatment.~2. Individual is receiving a stable medication regimen including 3 or more anti-hypertensive medications of different classes, of which one must be a diuretic that is expected to be maintained without changes for at least 6 months.~3. Individual has an office systolic blood pressure of 160 mm Hg based on an average of 3 blood pressure readings measured at screening visits~4. Individual or legally authorized representative agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.~Exclusion Criteria:~1. Individual has renal artery anatomy that is ineligible for treatment including:~   * Main renal arteries with less than 4 mm diameter or with less than 20 mm treatable length~  * Multiple renal arteries where the main renal artery is estimated to supply less than 75 percent of the kidney.~  * Renal artery stenosis more than 50 percent or renal artery aneurysm in either renal artery.~  * A history of prior renal artery intervention including balloon angioplasty or stenting.~2. Individual has an estimated glomerular filtration rate of less than 45mL per min per 1.73m2, using the MDRD calculation.~3. Individual has had more than 1 in-patient hospitalization for a hypertensive crisis within the past year.~4. Individual has type 1 diabetes mellitus.~5. Individual has had 1 or more episodes of symptomatic orthostatic hypotension within the past year or during the screening process.~6. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea.~7. Individual has primary pulmonary hypertension.~8. Individual has known secondary causes of hypertension, such as untreated pheochromocytoma, Cushing's Disease, coarctation of the aorta, hyperthyroidism, or hyperparathyroidism.~9. Individual has experienced a myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within 6 months of the screening period, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques.~10. Individual has a scheduled or planned surgery or cardiovascular intervention in the next 6 months.~11. Individual has a condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement using the protocol specified automatic blood pressure monitor~12. Individual has severe cardiac valve stenosis for which, in the opinion of the Investigator, a significant reduction of blood pressure is contraindicated.~13. Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study~14. Individual is pregnant, nursing or planning to be pregnant.~15. Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.~16. Individual is currently enrolled in another investigational drug or device trial. For the purposes of this protocol, participants involved in extended follow-up trials for products that were investigational but are currently commercially available are not considered enrolled in an investigational trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Symplicity renal denervation system (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).